Beam Therapeutics announced robust first quarter 2026 financial results with $1.2 billion in cash and progress in its gene-editing pipeline. Key highlights include positive Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency, selection of the 60 mg dose for pivotal trials starting in late 2026, and publication of BEACON trial data for risto-cel in sickle cell disease with a planned biologics license application by year-end 2026. The company also plans to file an IND for BEAM-304 in phenylketonuria and expects initial data from BEAM-301 in glycogen storage disease type Ia this year. With a strong cash runway into mid-2029, Beam is positioned to advance multiple precision genetic medicine programs toward commercialization.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
